- Home
- MODD vs RLYB Comparison
MODD vs RLYB Comparison
Compare MODD & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | RLYB |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 28.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MODD | RLYB |
|---|---|---|
| Price | $0.47 | $4.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 171.3K | 23.3K |
| Earning Date | 02-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $0.28 | $1.76 |
| 52 Week High | $1.29 | $6.75 |
Technical Indicators
Market Signals| Indicator | MODD | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 93.88 |
| Support Level | $0.42 | $0.56 |
| Resistance Level | $0.49 | $5.00 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | 0.45 |
| Stochastic Oscillator | 48.41 | 88.57 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.